Biotechnology company · NBIX

Neurocrine Biosciences
clinical trial
pipeline

Registry checked

Published

Direclidine is linked to 5 distinct active studies: 5 recruiting. Osavampator is linked to 5 distinct active studies: 5 recruiting.

Phase 2 study NCT07365462 in Tardive Dyskinesia lists estimated primary completion in February 2027. Phase 3 study NCT06786624 in Major Depressive Disorder lists estimated primary completion in July 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

18active trials
as lead sponsor
  • Phase 10
  • Phase 25
  • Phase 312
  • Phase 41
  • Phase not recorded0

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

00 trials30 completed days

No eligible observations recorded in this period.

Recruitment statusPrimary completionEnrolmentFirst observedOther

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200000000
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-280000000
2026-10-290000000
2026-10-300000000
2026-10-310000000
Type totals0000000 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Direclidine

Canonical investigational asset

5
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
Bipolar I Disorder · Mania · Schizophrenia
Next primary completion
Oct 2027 · estimated
Open drug

Osavampator

Canonical investigational asset

5
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
Major Depressive Disorder
Next primary completion
Jul 2027 · estimated
Open drug

Valbenazine

INGREZZA

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 31
  • Phase 41
  • Phase not recorded0
Studied condition
Bipolar Disorder · Chorea, Huntington · Major Depressive Disorder
Next primary completion
Not reported
Open drug

Crinecerfont

CRENESSITY

2
Active trials
0
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 20
  • Phase 32
  • Phase 40
  • Phase not recorded0
Studied condition
Congenital Adrenal Hyperplasia
Next primary completion
Not reported
Open drug

NBI-1065890

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Tardive Dyskinesia
Next primary completion
Feb 2027 · estimated
Open drug

NBI-1117570

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 10
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Schizophrenia
Next primary completion
Aug 2027 · estimated
Open drug

16 of 18 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 16 of 18 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Neurocrine Biosciences trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia
NBI-1065890

NCT07365462

Phase 2 · Recruiting

Trial source and qualifications

Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

1 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 06 Feb 2026 · actual
    Primary completion: Feb 2027 · estimated
    Study completion: Mar 2027 · estimated

    2021202220232024202520262027202820292030
    Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
    Osavampator

    NCT06786624

    Phase 3 · Recruiting

    Trial source and qualifications

    Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

    1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    1 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 22 Jan 2025 · actual
      Primary completion: Jul 2027 · estimated
      Study completion: Jul 2027 · estimated

      2021202220232024202520262027202820292030
      NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
      Osavampator

      NCT06911112

      Phase 3 · Recruiting

      Trial source and qualifications

      NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 31 Mar 2025 · actual
        Primary completion: Jul 2027 · estimated
        Study completion: Jul 2027 · estimated

        2021202220232024202520262027202820292030
        NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)
        Osavampator

        NCT06963021

        Phase 3 · Recruiting

        Trial source and qualifications

        NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD)

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 30 May 2025 · actual
          Primary completion: Jul 2027 · estimated
          Study completion: Jul 2027 · estimated

          2021202220232024202520262027202820292030
          Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia
          NBI-1117570

          NCT07288333

          Phase 2 · Recruiting

          Trial source and qualifications

          Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

          2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          2 inspected observations omitted. At most three verified observations are shown, not full history.

            Start: 16 Feb 2026 · actual
            Primary completion: Aug 2027 · estimated
            Study completion: Aug 2027 · estimated

            2021202220232024202520262027202820292030
            NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
            Direclidine

            NCT06963034

            Phase 3 · Recruiting

            Trial source and qualifications

            NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia

            Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

            1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

            ClinicalTrials.gov source

            1 inspected observations omitted. At most three verified observations are shown, not full history.

              Start: 08 May 2025 · actual
              Primary completion: Oct 2027 · estimated
              Study completion: Oct 2027 · estimated

              2021202220232024202520262027202820292030

              Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

              6 selected of 14 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 2 actual primary completions, 0 untyped primary completions, 0 past estimates, 1 outside the horizon, 0 contradictory dates.

              04 / Therapeutic focus

              Where the activity is

              12

              active trials in Psychiatry & Addiction

              Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

              Active trials by primary therapeutic area

              • Psychiatry & Addiction12 trials
              • Renal & Urology3 trials
              • Neurology2 trials
              • Unmapped1 trials
              • Healthy volunteers0 trials

              Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

              06 / Related companies

              All companies
              S

              Sanofi

              Shared indexed programme context · 1 selected asset

              T

              Takeda

              Shared indexed programme context · 1 selected asset

              Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

              Sources, scope and methodology

              ClinicalTrials.gov lead-sponsor scope

              Canonical current-owner attribution covers 86 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Neurocrine Biosciences. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

              ClinicalTrials.gov

              Attribution coverage

              86 distinct registry candidates produced 86 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

              Indexed enrichment

              83 scoped records have indexed enrichment and 3 do not. Missing enrichment does not remove a trial from cohort counts.

              Scope observation

              The successful attribution check completed at 2026-11-01T01:40:33.062Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 9631910b9ab24e9089de5fe0c6a59f35b73730d1acbc0d2b9271bcfea6db4bce.

              Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

              Dated canonical-attribution snapshot: 86 mapped lead-sponsored clinical studies across all statuses. 83 have indexed enrichment, 3 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

              Keep following
              what matters.

              Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

              Build your watch

              Choose what to track in the watch builder.